Quick Answer
Compass Therapeutics, Inc. reported Stockholders Equity of $196.79 million for the year ending 2025.
- Compass Therapeutics, Inc. showed an increase of +57.1% in Stockholders Equity from 2024 to 2025.
- This data is from Compass Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$43.0 thousand | Q3 2018: -$51.6 thousand | Q1 2019: -$95.29 million | Q2 2019: -$103.91 million | Q3 2019: -$112.22 million | Q1 2020: -$124.76 million | Q2 2020: $53.25 million | Q3 2020: $47.29 million | Q1 2021: $33.47 million | Q2 2021: $28.88 million | Q3 2021: $23.89 million | Q1 2022: $134.49 million | Q2 2022: $126.93 million | Q3 2022: $116.12 million | Q1 2023: $175.27 million | Q2 2023: $168.29 million | Q3 2023: $160.05 million | Q1 2024: $157.06 million | Q2 2024: $146.10 million | Q3 2024: $138.40 million | Q1 2025: $110.28 million | Q2 2025: $93.21 million | Q3 2025: $209.61 million.
- Over the full 11 years of available data (2018 to 2025), Compass Therapeutics, Inc.'s Stockholders Equity has grown by 569,650.2%.
- Historical annual values: Fiscal year 2025: $196.79 million | Fiscal year 2024: $125.23 million | Fiscal year 2023: $148.54 million | Fiscal year 2022: $181.64 million | Fiscal year 2021: $140.08 million | Fiscal year 2020: $39.95 million | Fiscal year 2020: -$108.1 thousand | Fiscal year 2019: $11.27 million | Fiscal year 2019: -$70.6 thousand | Fiscal year 2018: -$84.77 million | Fiscal year 2018: -$34.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: